Print ISSN 1738-3684
On-line ISSN 1976-3026
 
 
Abstract
Volume 7. Number 1. Pages 55-9 (2010) - Original Article  
   
Antidepressant-Induced Sexual Dysfunction among Newer Antidepressants in a Naturalistic Setting
 
Kyoung-Uk Lee1;Young Min Lee2;Ji-Min Nam1;Hae-Kook Lee1;Yong-Sil Kweon1;Chung Tai Lee1; and Tae-Youn Jun1;
1;Department of Psychiatry, College of Medicine, The Catholic University of Korea, Seoul,
2;Department of Psychiatry, School of Medicine, Pusan National University, Busan, Korea


Objective : Antidepressants used to treat depression are frequently associated with sexual dysfunction. Sexual side effects affect the patient's quality of life and, in long-term treatment, can lead to non-compliance and relapse. However, studies covering many antidepressants with differing mechanisms of action were scarce. The present study assessed and compared the incidence of sexual dysfunction among different antidepressants in a naturalistic setting. 

Methods : Participants were married patients diagnosed with depression, per DSM-IV diagnostic criteria, who had been taking antidepressants for more than 1 month. We assessed the participants via the Arizona Sexual Experiences Scale (ASEX), Beck Depression Inventory (BDI), and State-Trait Anxiety Inventory (STAI), and assessed their demographic variables, types and dosages of antidepressants, and duration of antidepressant use via their medical records. 

Results : One hundred and one patients (46 male, 55 female, age 42.2±7 years) completed the instruments. Thirteen were taking fluoxetine (mean dose 21.3±8.5 mg/day), 24 were taking paroxetine (mean dose 20.4±7.2 mg/day), 20 taking citalopram (mean dose 22.1±6.5 mg/day), 22, venlafaxine (mean dose 115.7±53.2 mg/day) and 22, mirtazapine (mean dose 18±8.7 mg/day). Mean ages, sex ratios, and BDI and STAI scores did not differ significantly across antidepressants. A substantial number of participants (46.5%, n=47) experienced sexual dysfunction. The prevalence of sexual dysfunction differed across drugs: citalopram 60% (n=12), venlafaxine 54.5% (n=12), paroxetine 54.2% (n=13), fluoxetine 46.2% (n=6), and mirtazapine 18.2% (n=4). Regression analyses revealed the significant factors for sexual dysfunction were being female, total scores on the BDI and SAI, and type of antidepressant (F=4.92, p<0.0001). Of the antidepressants, the mirtarzapine group's total ASEX score was significantly lower than the scores of the citalopram, fluoxetine, and paroxetine groups.

Conclusion : The incidence of sexual dysfunction was substantially high during antidepressant treatment. The incidence of sexual dysfunction differed among antidepressants having different mechanisms of action. Our study suggests the need for clinicians to consider the impact of pharmacotherapy on patients' sexual functioning in the course of treatment with antidepressants. 


Key Words
Depression;Sexual dysfunction;Antidepressants.
 
   
 


HOME  |   PRIVACY POLICY  |  CONTACT US SITE MAP


COPYRIGHT© 2010 KOREAN NEUROPSYCHIATRIC ASSOCIATION ALL RIGHT RESERVED. PRODUCED. BY ML COMMUNICATIONS. CO.,LTD.

This Article

SERVICE